Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Kenealy
Melita K
MK
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. kenealy@petermac.org
Prince
H Miles
HM
Hönemann
Dirk
D
D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects*; D011719:Pyrazines / Q000009:adverse effects*; D015275:Tumor Lysis Syndrome / Q000209:etiology*
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib